N@N

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX), Down By 9.87% ($0.60) From $6.102 After BUYINS.NET Report Predicted Weakness Afte

^{Published on 2012-08-06 07:46:22 - WOPRAI}
 

August 6, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, August 1st 2012 stating that Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) was expected to be Down After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=cpix&id=297372

At the time this story was written, Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is Down By 9.87% ($0.60) From $6.102 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) - Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of branded prescription products for the hospital acute care and gastroenterology markets primarily in the United States. Its product portfolio includes Acetadote (acetylcysteine) injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for pain and fever; and Kristalose (lactulose), a prescription laxative administered orally for the treatment of constipation. The company has a collaboration agreement with Vanderbilt University to develop a palliative treatment for fluid buildup in the lungs of cancer patients; and a novel treatment to improve renal function in patients with hepatorenal syndrome. It also has collaboration agreements with the University of Mississippi to develop an injectable anti-infective to treat fungal infections in immuno-compromised patients; and the University of Tennessee to develop a novel asthma therapeutic to prevent remodeling of airway smooth muscle to reduce asthmatic reaction in pediatric patients. Cumberland Pharmaceuticals was founded in 1999 and is headquartered in Nashville, Tennessee.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net